SURF Stock - Surface Oncology, Inc.
Unlock GoAI Insights for SURF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $30.00M | $2.69M | $126.16M | $15.36M | $59.42M |
| Gross Profit | $30.00M | $2.69M | $126.16M | $15.36M | $59.42M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-61,869,000 | $-76,013,000 | $61.59M | $-57,366,000 | $-9,151,000 |
| Net Income | $-65,303,000 | $-79,462,000 | $59.34M | $-53,004,000 | $-6,597,000 |
| Net Margin | -217.7% | -2957.3% | 47.0% | -345.1% | -11.1% |
| EPS | $-1.17 | $-1.80 | $1.67 | $-1.90 | $-0.33 |
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteEarnings History & Surprises
SURFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Jul 31, 2024 | — | — | — | — |
Q2 2024 | May 2, 2024 | — | — | — | — |
Q1 2024 | Mar 7, 2024 | — | — | — | — |
Q4 2023 | Nov 1, 2023 | $-0.36 | $-0.39 | -8.3% | ✗ MISS |
Q3 2023 | Aug 2, 2023 | $0.34 | $0.41 | +20.6% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $0.37 | $0.33 | -10.8% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $0.27 | $0.35 | +29.6% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $0.46 | $0.39 | -15.2% | ✗ MISS |
Q3 2022 | Aug 3, 2022 | $0.44 | $0.46 | +4.5% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $0.28 | $0.13 | -53.6% | ✗ MISS |
Q1 2022 | Mar 2, 2022 | $0.10 | $0.52 | +420.0% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $0.36 | $0.44 | +22.2% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $0.31 | $0.44 | +41.9% | ✓ BEAT |
Q2 2021 | May 5, 2021 | $0.40 | $0.37 | -7.5% | ✗ MISS |
Q1 2021 | Mar 9, 2021 | $0.22 | $1.56 | +609.1% | ✓ BEAT |
Q4 2020 | Nov 10, 2020 | $0.41 | $0.39 | -4.9% | ✗ MISS |
Q3 2020 | Aug 11, 2020 | $0.51 | $0.44 | -13.7% | ✗ MISS |
Q2 2020 | May 12, 2020 | $0.43 | $0.74 | +72.1% | ✓ BEAT |
Q1 2020 | Mar 10, 2020 | $0.57 | $0.57 | 0.0% | = MET |
Q4 2019 | Nov 12, 2019 | $0.58 | $0.61 | +5.2% | ✓ BEAT |
Latest News
Frequently Asked Questions about SURF
What is SURF's current stock price?
What is the analyst price target for SURF?
What sector is Surface Oncology, Inc. in?
What is SURF's market cap?
Does SURF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SURF for comparison